Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conatus Pharmaceuticals Inc.

www.conatuspharma.com

Latest From Conatus Pharmaceuticals Inc.

Novartis, Pfizer Advance Their NASH Ambitions Separately, As Partners

Novartis thinks tropifexor may prove to be best-in-class FXR agonist, while Pfizer notes the complementary activity of its ACC and DGAT2 inhibitors. Their NASH trial collaboration is heading toward a Phase II launch in 2020.

Business Strategies Research and Development Strategies

Novartis Adds To NASH Pipeline By Licensing Pliant’s Integrin Inhibitor

Deal for preclinical asset adds an anti-fibrotic mechanism to Novartis’ NASH program. Pliant produced preclinical data showing strong anti-fibrotic effect.

Deals Research and Development Strategies

Boehringer Adds Yuhan’s First-In-Class Dual Agonist To NASH Portfolio

Yuhan reaches $870m NASH licensing-out deal with Boehringer, touting its competitiveness in the space after earlier alliance with Gilead. The collaboration for first-in-class GLP-1/FGF21 dual agonist is poised to beef up German firm's R&D expertise in cardiometabolic disease.

South Korea Deals

Conatus Accepts Defeat For Emricasan In NASH

After multiple Phase IIb trial failures, Conatus says it will fulfill contractual obligations and consider strategic alternatives. Partner Novartis was already focused on other candidates and partnerships in NASH.

Clinical Trials Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Conatus Pharmaceuticals Inc.
  • Senior Management
  • Steven J Mento, PhD, Pres. & CEO
    Michelle L Vandertie, VP, Fin.
    Daniel L Ripley, VP, Bus. Dev. & Program Alliance Mgt.
    Alfred P Spada, PhD, EVP, R&D & CSO
  • Contact Info
  • Conatus Pharmaceuticals Inc.
    Phone: (858) 376-2600
    16745 West Bernardo Dr.
    Ste. 200
    San Diego, CA 92127
    USA
UsernamePublicRestriction

Register